Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Taltz® (ixekizumab) – New indication
December 1, 2017 – Eli Lilly announced the FDA approval of Taltz (ixekizumab), for the treatment of adult patients with active psoriatic arthritis (PsA).
